• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Celgene Corporation

Celgene Corporation

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Celgene Corporation to Announce Fourth Quarter and Full-Year 2016 Results on January 26, 2017

    Celgene Corporation to Announce Fourth Quarter and Full-Year 2016 Results on January 26, 2017

  2. Celgene Corporation to Present at the 35th Annual J.P. Morgan Healthcare Conference

    Celgene Corporation to Present at the 35th Annual J.P. Morgan Healthcare Conference

  3. Celgene Corporation Announces Preliminary 2016 Unaudited Results and 2017 Financial Guidance

    Celgene Corporation Announces Preliminary 2016 Unaudited Results and 2017 Financial Guidance

  4. Regenacy Pharmaceuticals HDAC1,2 Inhibitors Demonstrate Single-agent and Synergistic Activity with Azacitidine (Vidaza®) in Preclinical Models of Acute Myeloid Leukemia

    Regenacy Pharmaceuticals HDAC1,2 Inhibitors Demonstrate Single-agent and Synergistic Activity with Azacitidine (Vidaza®) in Preclinical Models of Acute Myeloid Leukemia

  5. Bloom Burton & Co. Announces the Inaugural Bloom Burton Award Gala

    Bloom Burton & Co. Announces the Inaugural Bloom Burton Award Gala

  6. The investing insanity of trying to find the next Amazon

    The investing insanity of trying to find the next Amazon

  7. Share Repurchase: Potential Signal of Undervaluation and Outperformance

    Celgene's CELG prized drug Revlimid was approved for multiple myeloma in June, and third-quarter results gave us our first look at sales for its use in treating a second form of blood cancer. While Revlimid's multiple myeloma launch was strong and did not appear to cannibalize legacy drug ...

  8. Will the Election Affect Earnings?

    If Americans sweep Democrats into office, these healthcare proposals could get a shot in the arm. Here’s how they would have an impact on earnings.

  9. Tuttle Tactical Management Weekly Market Notes

    Tuttle Tactical Management, LLC is an investment adviser registered with the U.S. Securities and Exchange Commission. You should not assume that any discussion or information contained in this letter serves as the receipt of, or as a substitute for, personalized investment advice from Tuttle Tactical Management, LLC. It is published solely for informational purposes and is not to be construed as a solicitation nor does it constitute advice, investment or otherwise. To the extent that a reader has questions regarding the applicability of any specific issue discussed above to his/her individual situation, he/she is encouraged to consult with the professional adviser of his/her choosing. A copy of our written disclosure statement regarding our advisory services and fees is available upon request. Our comments are an expression of opinion. While we believe our statements to be true, they always depend on the reliability of our own credible sources. Past performance is no guarantee of ...

  10. Our Outlook for the Credit Markets

    Widening investment-grade credit spreads and rising interest rates lead to losses.

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.